Victory Capital Management Inc. Raises Stock Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)

Victory Capital Management Inc. increased its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 22.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 18,522 shares of the biopharmaceutical company’s stock after purchasing an additional 3,424 shares during the quarter. Victory Capital Management Inc.’s holdings in TG Therapeutics were worth $316,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the stock. New York State Common Retirement Fund lifted its stake in shares of TG Therapeutics by 1.2% during the 4th quarter. New York State Common Retirement Fund now owns 56,208 shares of the biopharmaceutical company’s stock worth $960,000 after purchasing an additional 663 shares during the last quarter. Handelsbanken Fonder AB increased its position in TG Therapeutics by 48.9% during the 4th quarter. Handelsbanken Fonder AB now owns 33,200 shares of the biopharmaceutical company’s stock valued at $567,000 after buying an additional 10,900 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in TG Therapeutics by 27.8% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 33,742 shares of the biopharmaceutical company’s stock valued at $576,000 after buying an additional 7,330 shares in the last quarter. Strs Ohio acquired a new position in TG Therapeutics during the 4th quarter valued at about $298,000. Finally, Valeo Financial Advisors LLC increased its position in TG Therapeutics by 2.4% during the 4th quarter. Valeo Financial Advisors LLC now owns 63,300 shares of the biopharmaceutical company’s stock valued at $1,081,000 after buying an additional 1,500 shares in the last quarter. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on TGTX. B. Riley upped their target price on TG Therapeutics from $24.00 to $29.00 and gave the company a “buy” rating in a research report on Monday, February 5th. The Goldman Sachs Group upped their target price on TG Therapeutics from $12.00 to $13.00 and gave the company a “neutral” rating in a research report on Thursday, February 29th. JPMorgan Chase & Co. reaffirmed an “overweight” rating and set a $25.00 target price on shares of TG Therapeutics in a research report on Thursday, April 18th. LADENBURG THALM/SH SH upped their target price on TG Therapeutics from $39.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday, May 2nd. Finally, HC Wainwright increased their price objective on TG Therapeutics from $45.00 to $49.00 and gave the company a “buy” rating in a report on Thursday, May 2nd. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, TG Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $29.83.

Insider Buying and Selling

In related news, Director Laurence N. Charney sold 22,000 shares of the firm’s stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $15.97, for a total transaction of $351,340.00. Following the sale, the director now directly owns 215,229 shares of the company’s stock, valued at $3,437,207.13. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 9.20% of the stock is owned by corporate insiders.

TG Therapeutics Stock Down 1.6 %

Shares of TGTX stock opened at $16.71 on Friday. The stock’s 50-day simple moving average is $15.41 and its 200-day simple moving average is $15.39. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.84 and a current ratio of 3.62. The firm has a market capitalization of $2.58 billion, a PE ratio of 72.65 and a beta of 2.33. TG Therapeutics, Inc. has a fifty-two week low of $6.46 and a fifty-two week high of $29.32.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.02). The firm had revenue of $63.47 million during the quarter, compared to analyst estimates of $54.60 million. TG Therapeutics had a net margin of 14.24% and a return on equity of 31.34%. The firm’s revenue for the quarter was up 713.5% on a year-over-year basis. During the same period in the prior year, the company posted ($0.28) earnings per share. Equities analysts expect that TG Therapeutics, Inc. will post -0.01 earnings per share for the current year.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.